Hematoporphyrin Phototherapy of Malignant Tumors
More than ten years have elapsed since Diamond et al. demonstrated1 the possibility of using the photodynamic properties of hematoporphyrin (Hp) to cure malignant tumors in vivo. At present, the so-called photoradiation therapy (PRT) is under clinical investigation as a new technique to treat a wide variety of solid tumors. Up to now about 2000 patients have been treated with PRT in several different countries2. Generally, PRT is performed by using the hematoporphyrin derivative (HpD) as the photosensitizing agent. HpD is intravenously injected; after 2–5 days, the malignant lesions are exposed to visible light of wavelengths between 620 and 640 nm.
KeywordsBasal Cell Carcinoma Light Dose Photosensitize Agent Endogenous Porphyrin Quartz Optical Fiber
Unable to display preview. Download preview PDF.
- 1.I. Diamond, A. F. McDonagh, C. B. Wilson, S. G. Granelli, S. Nielsen, and R. Jaenicke, Photodynamic therapy of malignant tumors, Lancet 1175 (1972).Google Scholar
- 2.T. J. Dougherty, An overview of the status of photoradiation therapy, in:”Porphyrin localization and treatment of tumors,” D. Doiron, ed., Alan R. Liss Inc., New York (1983).Google Scholar
- 3.L. Tomio, F. Calzavara, P. L. Zorat, E. Rossi, E. Reddi, and G. Jori, Photoradiation therapy for cutaneous and subcutaneous tumors using hematoporphyrin, in:”Porphyrin localization and treatment of tumors,” D. Doiron, ed., Alan R. Liss Inc., New York (1983).Google Scholar
- 4.G. Jori, E. Reddi, L. Tomio, B. Salvato, P. L. Zorat, and F. Calzavara, Time-course of hematoporphyrin distribution in selected tissues of normal rats and in ascites hepatoma, Tumori 65:43 (1979).Google Scholar
- 7.L. Tomio, P. L. Zorat, G. Jori, E. Reddi, L. Corti, and F. Calzavara, Elimination pathway of hematoporphyrin from normal and tumor-bearing rats, Tumori 68:283 (1982).Google Scholar